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Axonal regeneration after peripheral nerve injury is impaired in diabetes, but its precise 
mechanisms have not been elucidated. In this paper, we summarize the progress of 
research on altered axonal regeneration in animal models of diabetes and cultured nerve 
tissues exposed to hyperglycemia. Impaired nerve regeneration in animal diabetes can 
be attributed to dysfunction of neurons and Schwann cells, unfavorable stromal envi-
ronment supportive of regenerating axons, and alterations of target tissues receptive to 
reinnervation. In particular, there are a number of factors such as enhanced activity of 
the negative regulators of axonal regeneration (e.g., phosphatase and tensin homolog 
deleted on chromosome 10 and Rho/Rho kinase), delayed Wallerian degeneration, alter-
ations of the extracellular matrix components, enhanced binding of advanced glycation 
endproducts (AGEs) with the receptor for AGE, and delayed muscle reinnervation that 
can be obstacles to functional recovery after an axonal injury. It is also noteworthy that 
we and others have observed excessive neurite outgrowth from peripheral sensory gan-
glion explants from streptozotocin (STZ)-diabetic mice in culture and enhanced regen-
eration of small nerve fibers after sciatic nerve injury in STZ-induced diabetic rats. The 
excess of abortive neurite outgrowth may lead to misconnections of axons and target 
organs, which may interfere with appropriate target reinnervation and functional repair. 
Amelioration of perturbed nerve regeneration may be crucial for the future management 
of diabetic neuropathy.
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iNTRODUCTiON
In contrast to the unsuccessful axonal regeneration in the central nervous system (CNS) in adult 
mammals, neurons in the peripheral nervous system (PNS) have a potential to grow new axons 
after injury. Successful nerve regeneration with functional recovery in the PNS can be attributed to 
both intrinsic and extrinsic factors, such as the ability of neurons and/or Schwann cells to regenerate 
neurites, the distal environment supportive of axon regrowth, and the target tissues receptive to rein-
nervation (Figure 1) (1). Although growth inhibitory molecules, such as chondroitin sulfate pro-
teoglycans and myelin-associated glycoprotein, are present in both adult CNS and PNS, Wallerian 
FiGURe 1 | The process of peripheral nerve regeneration after injury.
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degeneration of the peripheral nerves distal to the injury 
provides an optimal environment for axonal sprouting from the 
injured neurons (1, 2). The sequence of cellular events during 
Wallerian degeneration includes Schwann cell activation and 
proliferation, macrophage recruitment, elimination of axonal 
and myelin debris, and synthesis of neurotrophic and chemo-
tactic factors. However, axonal regeneration and reinnervation 
depends on appropriate contact of regenerating axonal sprouts 
with Schwann cell basal laminae in the distal nerve segment. 
Currently, clinical approaches to repair axonal injury are still far 
from satisfactory (3).
Diabetic peripheral neuropathy is one of the most common 
and intractable complications of diabetes mellitus, and its 
prevalence correlates closely with the degree and duration of the 
disease (4). Impaired axonal regeneration is one of the salient fea-
tures of diabetic neuropathy; however, its pathogenesis remains 
to be elucidated (5). In this paper, we review the findings from 
recent studies that focus on how diabetes affects the intrinsic and 
extrinsic factors of peripheral nerve regeneration. In addition, we 
discuss our own results from in vivo and in vitro studies, which 
indicate that defective neurite outgrowth after axonal injury 
occurs under diabetic conditions (6–8).
iMPAiReD AXONAL ReGeNeRATiON iN 
ANiMAL MODeLS OF DiABeTeS
Impaired axonal regeneration following peripheral nerve injury 
is a characteristic feature of diabetic neuropathy and has been 
documented in experimental diabetic animals [e.g., strepto-
zotocin (STZ)-diabetic rats (9) and mice (10), biobreeding 
Worcester (BB/Wor) rats (11), and Goto-Kakizaki rats (12)]. We 
classify these animal studies into the three categories indicated 
in italics in Section “Introduction” and briefly introduce recent 
studies focusing on the abnormalities in each category (Figure 2).
Altered Biological Properties of Neurons 
and Schwann Cells for Axonal 
Regeneration in Diabetes
Alterations in the biological properties of neurons and Schwann 
cells under diabetic conditions are likely to affect neurite out-
growth (5, 13, 14). So far, polyol pathway hyperactivity (11), 
altered tubulin and neurofilament expression (15), oxidative 
stress (16), and reduced synthesis/transport of neurotrophic 
factors (17, 18) have been implicated in the deficient axonal 
regeneration in diabetic animals. In addition to those studies, 
upregulation of growth inhibitory molecules in diabetic neurons 
and/or Schwann cells has recently attracted much attention. 
Phosphatase and tensin homolog deleted on chromosome 10 
(PTEN) is an intrinsic inhibitor of phosphoinositide-3-kinase 
Akt signaling pathway and has been suggested to negatively 
regulate axonal regeneration in the CNS (19) and PNS (20). 
PTEN is predominantly expressed in small IB4-binding dorsal 
root ganglion (DRG) neurons, axons, and Schwann cells (20). Its 
neuronal expression is significantly elevated in STZ-diabetic mice 
relative to that in normal littermates (21). Moreover, knockdown 
of PTEN in DRG by non-viral retrograde short interfering RNA 
uptake was shown to accelerate electrophysiological recovery 
of the peripheral nerve and myelinated axonal regrowth as well 
as skin reinnervation after sciatic nerve crush injury in diabetic 
mice (21). These findings imply that suppression of PTEN activity 
can be a novel strategy for restoration of the regenerative capacity 
of diabetic neurons.
The small G protein Rho and its downstream target Rho kinase 
(ROCK) regulate cell adhesion, migration, and proliferation 
through actin cytoskeleton assembly and cell contraction (22). 
Rho and ROCK are recognized as potent inhibitors for axonal 
regeneration (23) and inactivation of Rho/ROCK has been 
shown to enhance axonal regeneration (24, 25). A recent study by 
Kanazawa et al. (26) suggested an involvement of Rho/ROCK in 
the pathogenesis of diabetic neuropathy. In their study, RhoA and 
ROCK activity in the sciatic nerve was enhanced in STZ-diabetic 
rats, and treatment with fasudil, a specific ROCK inhibitor, 
ameliorated reduced nerve conduction velocities in diabetic rats. 
In addition, several studies with rodent models of diabetes have 
argued for the efficacy of Rho/ROCK inhibitors against painful 
signs (27) and erectile dysfunction (28). However, there has been 
no direct evidence that Rho/ROCK inhibition restored deficient 
axonal regeneration in diabetic animals. Exendin-4 (Ex-4), a 
glucagon-like peptide 1 (GLP-1) receptor agonist, is now widely 
used for patients with type 2 diabetes because of its glucose-
dependent insulinotropic actions and somatostatin-dependent 
glucagon inhibition. In addition to such pancreatic actions, direct 
actions of GLP-1 mimetics on the nervous system have been a 
matter of interest. Ex-4 promoted neurite outgrowth of PC12 cells 
and adult rodent DRG neurons (29–31) and restored the neuro-
logical abnormalities of STZ-diabetic mice without normalizing 
blood glucose levels (30). Suppression of RhoA activity (31) and 
an inverse relationship between RhoA activity/expression and 
neurite outgrowth activity or viability of DRG neurons (32, 33) 
may be implicated in the mechanisms accounting for the neuro-
protective effects of Ex-4.
FiGURe 2 | The suggested abnormalities leading to impaired axonal regeneration in diabetic animals.
3
Sango et al. Axonal Regeneration in Diabetes
Frontiers in Endocrinology | www.frontiersin.org February 2017 | Volume 8 | Article 12
Unfavorable Distal environment for Axon 
Regrowth
Following peripheral nerve injury, the distal ends of axons and 
myelin sheaths undergo Wallerian degeneration that is a pre-
requisite for the subsequent axonal regrowth and reinnervation 
to the target tissues (5, 34). A delay in the process of Wallerian 
degeneration appears to be closely associated with impaired 
axonal regeneration in diabetic animals (11, 35). Excessive 
phosphorylation of neurofilaments in peripheral nerves can be a 
cause of delayed Wallerian degeneration in STZ-diabetic rats (35) 
because phosphorylated neurofilaments are resistant to degrada-
tion by proteases activated by axonal injury. Removal of axonal 
and myelin debris by activated Schwann cells and recruited 
macrophages contributes to the guidance of the pathway for 
axonal regeneration. Therefore, impaired activities of these 
cells in response to nerve injury under diabetic conditions may 
also be implicated in delayed Wallerian degeneration (10, 36). 
According to Chen et al. (37), retarded macrophage infiltration 
and impaired vascularization in the distal stump of the transected 
sciatic nerves was ameliorated in diabetic mice with AR defi-
ciency (AR−/−). As a consequence, diabetic AR−/− mice exhibited 
improved Wallerian degeneration and nerve regeneration with 
functional recovery relative to that in diabetic AR+/+ mice. These 
findings are consistent with the beneficial effects of AR inhibitors 
(ARIs) that restored nerve regeneration after injury in diabetic 
animals (11, 38). They also suggest the involvement of polyol 
pathway hyperactivity in the deficit of macrophage-associated 
process in Wallerian degeneration. However, given the fact that 
AR is predominantly expressed in Schwann cells and epineurial 
endothelial cells rather than macrophages in the PNS (39), it 
remains unclear how the increased polyol flux leads to impaired 
recruitment of macrophages.
The extracellular matrix (ECM) of the peripheral nerve 
provides scaffold for the cellular components to modulate their 
properties through interactions between the cell-surface recep-
tors (e.g., integrins) and their specific ligands on the ECM. Major 
ECM proteins, such as collagens, laminin, and fibronectin, have 
been shown to promote axonal regeneration in  vivo (40) and 
in vitro (13). Chondroitin sulfate proteoglycans are recognized 
as repulsive substrata for neurons in the PNS (41, 42). Thus, 
diabetes-induced alterations in the structure and function of the 
ECM components in the PNS appear to intervene the regenera-
tive responses of nerve fibers. Matrix metalloproteases (MMPs) 
are a family of zinc-dependent proteolytic enzymes responsible 
for the degradation and remodeling of ECM components (5). In 
the PNS, MMP-9 expression is rapidly upregulated at the sites 
of axonal injury and appears to have a major role in Wallerian 
degeneration. On the other hand, MMP-2, which expression 
is upregulated at later stages within the outgrowing neurites, 
may provide a more permissive environment for regeneration 
by removing inhibitory ECM molecules, such as chondroitin 
sulfate proteoglycans (43, 44). Ali et  al. (45) recently reported 
downregulation of the activity and expression of MMP-2 in 
the sciatic nerve of STZ-diabetic rats relative to that of normal 
rats. In addition, reduced neurite outgrowth of cultured DRG 
neurons on sciatic nerve cryosections from diabetic rats was 
partially rescued by pretreatment with active MMP-2. These 
findings suggest that impaired axonal regeneration in diabetes is 
attributable in part to the unfavorable microenvironment caused 
by reduced MMP-2.
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A significant increase in the content of advanced glycation 
endproducts (AGEs) in endoneurial ECM proteins was detected 
in chronic STZ-diabetic rats (46). Glycation of ECM proteins 
under exposure to long-term hyperglycemic conditions may 
affect cell–matrix interactions and make the proteins more 
resistant to protease digestion, thereby leading to impaired axonal 
regeneration (46, 47). Receptor for AGEs (RAGE) is a multiligand 
receptor of the immunoglobulin superfamily and interacts with 
not only AGEs but also various kinds of proinflammatory and/
or regulatory molecules, such as the S100 family of cytokines, 
high-mobility group box 1 protein, amyloid beta-peptide, 
lysophosphatidic acid, and mammalian diaphanous-1 (48). In 
the PNS, RAGE is predominantly expressed in Schwann cells 
and endothelial cells and upregulated in diabetes (49, 50). It is 
also recognized that RAGE expression becomes prominent in 
activated Schwann cells and infiltrating macrophages upon acute 
peripheral nerve injury (51). Juranek et al. (52) recently reported 
that RAGE-deficient diabetic mice exhibited improved axonal 
regeneration after sciatic nerve crush compared to diabetic wild 
mice. In their study, diabetes-induced decreases in the number 
of endoneurial blood vessels and regenerating neurites at the 
crush side were significantly restored in diabetic mice deficient 
of RAGE. They further investigated macrophage infiltration into 
the nervous tissue distal to the site of injury in RAGE-deficient 
diabetic mice. The population of proinflammatory type M1 mac-
rophages was significantly higher in diabetic wild-type mice than 
in non-diabetic ones; however, RAGE-deficient diabetic mice 
exhibited a decrease in the population of M1 macrophages and 
an increase in anti-inflammatory type M2 macrophages relative 
to those in diabetic wild-type mice. On the basis of these findings, 
the researchers hypothesized that impaired axonal regeneration 
in diabetic mice is, at least in part, attributed to RAGE-dependent 
alteration of macrophage polarization. In agreement with this 
finding, treatment of bone marrow-derived macrophages with 
AGEs promoted M2 macrophage polarization into the M1 
phenotype through the activation of RAGE/nuclear factor-κB 
pathway (53). In contrast, however, pharmacological inhibition of 
RAGE by soluble RAGE or F(ab′)2 fragments of antibodies raised 
to RAGE or its ligands suppressed axonal regeneration after 
sciatic nerve crush in non-diabetic mice (54). Other studies have 
also suggested that RAGE per se is a positive modulator for axonal 
regeneration in the PNS (55, 56). It remains to be solved why 
RAGE inactivation has such contrasting effects on axonal regen-
eration between the hyperglycemic and normoglycemic condi-
tions. The RAGE ligands other than AGEs, in particular, S100B, 
and high-mobility group box 1 have been suggested to activate 
the RAGE signaling pathway in Schwann cells and macrophages 
to promote their migration to injured sites, thereby contributing 
to axonal regeneration with functional repair (51, 57–59). Under 
diabetic conditions, however, the AGE–RAGE signaling axis that 
is detrimental to axonal regeneration may surpass the non-AGE-
mediated RAGE signaling axes described above.
Alterations of Target Tissues Receptive  
to Reinnervation
Reinnervation of the peripheral target tissues is the final stage 
of axonal regeneration. Atrophy and denervation in the target 
tissues disturb functional repair even if regenerating axons suc-
cessfully reach their targets (1). A body of evidence indicates that 
the impaired axonal regeneration in diabetes can be attributed 
largely to the derangement of neurons and Schwann cells and the 
unfavorable environments for axonal sprouting and elongation as 
described above. There are several studies, however, on diabetes-
induced alterations of target tissues receptive to reinnervation. 
Homs et al. (60) reported that muscle reinnervation was delayed 
in both non-obese diabetic (NOD) mice and STZ-diabetic mice 
following sciatic nerve crush, but the changes were more robust 
in NOD mice than in STZ mice. Reduced expression of neuro-
trophin-3 in muscles is suggested to be a cause of insufficient 
reinnervation and muscle weakness in diabetes (61). In addition, 
prosaposin-derived peptide TX14(A) restored nerve regenera-
tion deficits and muscle denervation atrophy after sciatic nerve 
crush in STZ-diabetic rats. In this setting, TX14(A) may exert 
direct effects on muscles in response to nerve injury rather than 
nerve regenerative capability (62). Additionally, reduced produc-
tion of neurotrophic molecules in diabetic skin may also affect 
epidermal reinnervation after axonal injury (63, 64).
eXCeSSive NeURiTe OUTGROwTH 
FROM GANGLiON eXPLANTS iN  
STZ-DiABeTiC MiCe
In 1991, we introduced cell culture system of dissociated DRG 
neurons from experimental diabetic animals (Figure 3) (65, 66). 
Since then, this system has been recognized as a useful tool to 
explore the changes of neurons that are exposed to hyperglycemia 
for a significant period of time and is now widely employed for 
the study of diabetic neuropathy (13, 67). However, it remains 
controversial whether the neurite outgrowth of diabetic DRG 
neurons is impaired, and the cell culture system of dissociated 
DRG neurons has the following problems for evaluation of axonal 
regeneration. First, there is a possibility that severely damaged 
neurons in diabetic animals are eliminated during the procedure 
of culture. Second, there is a topographic difference in the site 
of neurite outgrowth where neurites sprout from neuronal cell 
bodies in vitro, whereas axonal regeneration occurs at the sites of 
injury in vivo. Third, neurons are separated from other neurons 
and non-neuronal cells. It is thus likely that the effects of cellular 
interplay on axonal regeneration cannot be evaluated by this 
system. To overcome these issues, we have established a three-
dimensional culture system of ganglion explants in which adult 
peripheral ganglia with nerve fibers are embedded in collagen 
gel or Matrigel®, and neurite outgrowth from transected nerve 
stump has been evaluated (Figure  4) (13, 68). Because of the 
maintenance of cell-to-cell interactions, it may be reasonable 
to consider that the explant culture mimics axonal regeneration 
in vivo better than the use of dissociated cells. We introduced this 
culture system to vagal nodose ganglia and DRG of STZ-diabetic 
mice and found that the neurite outgrowth from transected nerve 
stump in diabetic mice was not diminished but rather enhanced 
(6, 7). These findings were contrary to our expectations and in 
stark contrast to those in previous studies in vivo. Since it is well 
accepted that hyperglycemia impairs neural function, enhanced 
neurite outgrowth in vitro in our study does not seem to imply 
FiGURe 4 | explant culture of adult mouse dorsal root ganglion. 
Neurites are elongating from transected nerve terminals. Bar = 100 µm.
FiGURe 3 | Dissociated cell culture of adult rat dorsal root ganglion 
neurons. Cells are fixed and immunostained with anti-βIII tubulin antibody. 
Bar = 100 µm.
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the acceleration of proper axonal regeneration after injury in 
diabetes. Considering that the explant culture lacks the process 
of Wallerian degeneration and subsequent regenerative events 
at the site distal to injury, it seems more likely that the excess 
of regenerating fibers in diabetes may impede appropriate target 
reinnervation and functional recovery. This hypothesis was sup-
ported by the findings of in vivo studies (5, 8, 69), which will be 
discussed in the next section. Gumy et al. (36) applied the explant 
culture system to normal adult mice and observed that exposure 
to high-glucose (60 mM) culture conditions resulted in retarda-
tion of neurite outgrowth and Schwann cell migration from DRG 
explants. These findings are in disagreement with those in our 
studies (6, 7) and may be accounted for by the differential effects 
of long-term (>3  weeks) hyperglycemia in  vivo in our study 
versus short-term (<1 week) high-glucose environments in vitro 
on neurite outgrowth in their study. In neither study, however, the 
hyperglycemic insults induced apoptotic cell death of DRG neu-
rons. These findings indicate that apoptosis (70, 71) is unlikely to 
be a major contributor to the impaired axonal regeneration in 
diabetic neuropathy.
iNCReASeD SMALL-FiBeR DeNSiTY 
AFTeR NeRve iNJURY iN  
STZ-DiABeTiC RATS
Using electron microscopy, Yasuda et al. (38, 69) evaluated the 
regenerative capacity of myelinated nerve fibers (MNFs) and 
unmyelinated nerve fibers (UNFs) in STZ-diabetic and normal 
control rats at 5 and 24  weeks after sciatic nerve crush. The 
number and size of regenerating MNFs after crush injury were 
significantly decreased in diabetic rats relative to those in control 
rats. The structural changes were consistent with the reduced 
motor nerve conduction velocity detected in diabetic rats with 
nerve crush (38). In contrast, the density and number of UNFs 
were markedly increased in both normal and diabetic groups 
at 5  weeks after injury, and these parameters returned to their 
baseline levels in normal control rats but not in diabetic rats at 
24  weeks after injury (69). Although the precise mechanisms 
accounting for the differential effects of hyperglycemia on the 
regenerative capacity of MNFs versus that of UNFs remain 
unclear, the authors inferred that the long-lasting impairment 
of regenerative capacity of UNFs in diabetes might disturb the 
proper connection between the nerve endings and target organs. 
This inference seems to be well fitted with our hypothesis based 
on the in vitro assays (6, 7). Moreover, they found amelioration 
of the reduced motor nerve conduction velocity and number 
and size of regenerating MNFs in the crushed nerves in diabetic 
rats treated with tolrestat, an ARI (38). There were no significant 
effects, however, on the regenerative capacity of UNFs in the ARI-
treated diabetic rats (69). ARI may therefore be more effective for 
regeneration of MNFs with functional repair than UNFs under 
diabetic conditions, and the effects may be dependent on the high 
expression of AR in the Schwann cells (39, 72).
By light microscopic and ultrastructural morphometric 
analyses, we recently evaluated nerve fiber regeneration from 
axotomized sciatic nerves of STZ-diabetic rats and non-diabetic 
control rats (8). Four weeks after axotomy, there was a significant 
increase in myelinated fiber density and total fiber number at 
the cut end in diabetic rats relative to those in control rats. In 
contrast, the average number of myelin lamellae per fiber, meas-
ured by electron microscopy equipped with a computer-assisted 
image analyzing system, was significantly reduced in diabetic rats 
relative to that in control rats. These findings indicate enhanced 
regeneration of thinly MNFs after axotomy in rats with experi-
mental diabetes. Impaired myelination of regenerated fibers 
may be attributable to metabolic disorders of Schwann cells 
and increased vulnerability of the myelin sheath to oxidative 
stress under diabetic conditions (73–75). Increased regenera-
tion of small nerve fibers in this study may be associated with 
6Sango et al. Axonal Regeneration in Diabetes
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the improper target reinnervation described above and painful 
phenotypes of diabetic neuropathy (76), but further evidence is 
required to support this contention.
TRANSLATiONAL FiNDiNGS iN PATieNTS 
wiTH DiABeTiC NeUROPATHY
Although the purpose of this paper is to overview altered axonal 
regeneration in experimental diabetes, several findings illustrated 
here are closely associated with those from clinical studies. For 
instance, the restorative effects of ARIs on MNF regeneration in 
diabetic rats (11, 38) were also indicated in the specimens of sural 
nerve biopsies from patients with diabetic neuropathy (77, 78). 
Exogenously applied neurotrophic factors, growth factors, and 
other biological molecules improved axonal regeneration and 
other neurological functions in animal models of diabetes (5, 17, 
18, 79); however, the translation of these molecules (e.g., NGF, 
BDNF, and VEGF) to humans has failed in clinical trials (80–82). 
These failures may be attributable to the irrelevance of animal 
models and outcome measures to the pathology and pathophysi-
ology of human diabetic neuropathy (83).
Because the loss of corneal nerves has been shown to correlate 
well with the severity of peripheral nerve damage, corneal con-
focal microscopy (CCM) is recognized as a novel non-invasive 
diagnostic modality for patients with diabetic neuropathy (84). 
CCM has also been applied to animal models of diabetes, and 
Yorek et  al. (85) reported that glycemic control by continuous 
administration of insulin in STZ-diabetic mice significantly 
restored corneal nerve innervation. In agreement with this study, 
long-term normoglycemia by simultaneous pancreas and kidney 
transplantation in patients with type 1 diabetes improved corneal 
nerve fiber density, branch density, and length (86). In contrast, 
the transplantation failed to ameliorate the loss of epidermal 
nerve fiber density that was evaluated by skin biopsies (87). These 
findings imply that CCM can be a more sensitive means than skin 
biopsies for the assessment of early nerve regeneration and repair 
after therapeutic interventions.
CONCLUSiON
Diabetes mellitus has been shown to affect peripheral nerve 
regeneration in various ways. In the first part of this paper, we 
reviewed the topics of axonal regeneration in animal models of 
diabetes from the viewpoint of intrinsic and extrinsic factors, in 
particular, focusing on the events that occurred at the sites distal 
to the injury. Delayed Wallerian degeneration, alterations in the 
structure and function of the ECM components, and enhanced 
AGE–RAGE signaling axis caused by hyperglycemia can be 
major obstacles to axonal regrowth after injury. In the second 
part, we illustrated the excessive regenerative capacity of small 
nerve fibers under diabetic conditions in vivo and in vitro (6–8, 
69). There is room for further investigation if these findings imply 
dysfunctional neurite outgrowth that disturbs appropriate target 
reinnervation and functional recovery. In addition, much more 
attention should be paid to the diabetes-induced abnormalities 
of target tissues receptive to reinnervation.
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